Lincoln Pharma … the next mid-cap pharma in the making …?

1. Expand International Markets: Grow in Canada, Australia, and the EU by leveraging certifications (TGA, EU) and increasing product registrations.
2. Grow Domestic Market: Focus on high-demand cardiac, diabetic, and dermatology segments, and increase medical representatives from 600 to 800 in the next 2 years.
3. Maximize Cephalosporin Plant Output: Scale the plant to contribute INR 55-65 crore in FY25, reaching INR 220-230 crore annually.
4. Launch New Products: Introduce new products, leveraging a pipeline of 750+ products under registration.
5. Capex Investment: Invest INR 25-30 crore over two years to boost capacity, funded by internal accruals.

Disc: Invested